Astra Zeneca recently sold half the rights to an antibody Parkinsons drug project to Takeda for $400m that isn't even in Phase 1 trials......Why did they sell half....prob because they don't think it works!! If they value the whole thing at $800m....a successful trial result with NTcell is arguably worth multiples more. My point is - don't underestimate the potential value here!! Its worth $500m short term IMHO
technical shmeknical, page-266
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.49M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $5.169K | 715.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 8014267 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1382834 | 9 |
View Market Depth
| Last trade - 12.28pm 06/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |